Oct 6, 2026 · 5 min listen · Last updated October 6, 2026
From storyflo. This is your daily audio brief. Hi, it's Chloe. October 6th. Ten in health — the one that made me re-read the abstract is at the top. Let's get into it. First, from STAT. STAT+: Can you live longer for $5,500?
Listen · storyflo · health and longevity
Daily Health & Wellness Brief · October 6th
0:00-5:24
Pick your daily storyteller
Subscribe to match with Theo, Jessica, Chloe, Mason, Brock — your voice, every brief.
Daily Health & Wellness Brief · October 6th · Storyflo
culture
Audio pre-rendered by Storyflo · cached + delivered from the edge
STAT+: Can you live longer for $5,500? Longevity clinics are the buzzy new trend at nonprofit hospitals
Longevity clinics are gaining traction, especially at nonprofit hospitals like Northwestern University, which recently launched a $5,500 annual package. This package includes various assessments, like the VO2 Max test, a measure of how well your body uses oxygen, aimed at providing a detailed look at your health and aging process. While these clinics promise a scientific approach to maintaining youthfulness, some experts are skeptical. They raise concerns about the high costs and question whether the tests offered truly lead to better health outcomes. The trend reflects a broader fascination with anti-aging solutions, but it’s important to consider the evidence behind these practices.
Lycia seeks IPO for antibody degrader work as TRexBio, Retension forge ahead
Lycia Therapeutics, a startup focused on protein degradation, has officially filed for an initial public offering, which is a significant step for them. Their work is based on research from Carolyn Bertozzi, a Nobel laureate, which adds a level of credibility to their science. This IPO could help them secure the funding needed to further develop their innovative antibody degrader therapies.
Meanwhile, Retension, another biotech company, is also making strides in the industry. They, like Lycia, are gearing up for their own Nasdaq debut. It’s an exciting time for these companies as they push forward in the biotech space, which has been gaining traction lately.
Overall, while the market can be unpredictable, the advancements in these companies suggest a growing interest in novel therapeutic approaches. It'll be interesting to see how these IPOs unfold and what they mean for the broader biotech landscape.
There's a growing movement in the restaurant world called Off The Table, urging chefs to stop serving farmed salmon, led by the UK charity WildFish. While their concerns about salmon farming—like pollution and disease—are valid, the argument oversimplifies the issue. Not all farmed salmon is created equal; how and where it's raised makes a big difference.
Instead of banning farmed salmon outright, the focus should be on improving farming practices. We can regulate and manage aquaculture to reduce its environmental impact, rather than eliminating it entirely. The real question is what happens if we remove farmed salmon from menus—will demand just shift to other fish or meats, potentially causing more harm?
We need to balance the need for nutritious food with sustainable practices. Responsible aquaculture can actually support wild fish populations by taking some pressure off them. The challenge is finding a way to produce food that meets global demand while protecting our ecosystems.
The article reflects on the concept of abundance, shifting the focus from simply wanting more to understanding how much we can actually handle. The author shares a personal experience of receiving an abundance of fresh herbs and grapples with the challenge of making space for them. This leads to a deeper contemplation about life: just because we can fit more in doesn’t mean we should.
The writer emphasizes that capacity is crucial; it’s not just about receiving more but being mindful of what we can genuinely care for. They highlight the idea that change doesn’t always have to come from crisis; sometimes, we need to let go of things that no longer serve us, even if they seem good. Ultimately, abundance is about having the space and energy to nurture what we already have, rather than stretching ourselves too thin.
The writer is buzzing with excitement about several projects in the works, although the details are still under wraps for now. Their website is temporarily down for updates, which means the online shop is closed, but you can still buy paintings directly through email. It’s a more personal touch, and they’ve been enjoying this method.
The f/LIGHT DECK is making a comeback after being out of stock for months, along with two new decks linked to their project, “Tell Me 3 Good Things,” set to launch this fall. If you’re interested in pre-orders, there’s a form to sign up for notifications.
Additionally, new benefits for paid subscribers are on the horizon, which could be a good incentive for those considering an upgrade. The writer expresses gratitude for the support and is eager to share more soon.
On a personal note, they’ve been busy making ginger-lemon shots and freezing them for winter, had a successful home repair with their washing machine, and enjoyed the refreshing breeze from open windows. They invite readers to share their own good things, keeping the positive energy flowing.
Opinion: Why the FDA should not approve an ineffective multicancer screening test
A recent opinion piece raises serious concerns about a cancer blood test that was studied in a large trial involving 140,000 people. The test didn’t meet its primary goal, which is a red flag for its effectiveness. Despite this, an advisory panel from the FDA has recommended it for approval. The situation is even more troubling because of a new law that could lead to taxpayers covering the costs of this test, even though it hasn’t proven to be effective. The piece questions how a test that fails to show clear benefits could still be on track for approval and funding, highlighting the need for more rigorous standards in evaluating medical tests.
Opinion: I’m a doctor. Here’s what I want the public to know about AI tools and health care costs
A recent study from Blue Cross Blue Shield raised eyebrows by suggesting that hospitals might be using artificial intelligence tools to boost their profits from insurers without actually improving patient care. This has sparked frustration among many, including doctors who see the potential of AI to enhance health outcomes. The concern is that while AI can help document patient conditions, it can also lead to inflated hospital bills due to the way comorbidities are factored into billing. This situation highlights a disconnect between the use of advanced technology and the real benefits it brings to patient care.
In this hospital, pulse oximeters went from overestimating to underestimating blood oxygen. Why?
Pulse oximeters became widely used during the Covid-19 pandemic, allowing people to easily check their blood oxygen levels at home. However, recent studies have highlighted a significant issue: these devices tend to overestimate blood oxygen levels, particularly in individuals with darker skin tones. This discrepancy can lead to a false sense of security, making patients of color seem healthier than they actually are, which can ultimately worsen health outcomes and deepen existing inequalities.
Interestingly, a new study from a hospital found that after adjusting their protocols, pulse oximeters began to underreport blood oxygen levels in these same populations. This shift raises important questions about how we can ensure these devices provide accurate readings for everyone. The findings underscore the need for ongoing scrutiny of medical tools and their impact on diverse populations, as well as the importance of equitable healthcare practices.
As we move forward, it's crucial to keep these disparities in mind and advocate for improvements in medical technology that serve all patients fairly. This is a reminder that while these tools can be helpful, they’re not perfect, and we need to be aware of their limitations.
Send this story to anyone — or drop the embed into a blog post, Substack, Notion page. Every play sends rev-share back to storyflo · health and longevity.